IMI launches final IMI2 Calls for proposals: Call 22 and Call 23

IMI will contribute a total of EUR 59 million to the projects funded under the Calls; these funds come from Horizon 2020 and will support the participation in the projects of organisations such as universities, small and medium-sized enterprises, and patient groups. EFPIA companies and IMI Associated Partners will contribute EUR 47 million, mostly as ‘in kind’ contributions (e.g. staff time, access to equipment, etc.).

Pierre Meulien, IMI Executive Director commented: ‘These final IMI2 Calls showcase the areas where IMI is best placed to make a difference. The topics on antimicrobial resistance, neurodegenerative disease and rare diseases demonstrate our commitment to addressing unmet medical needs that are too complex for any single organisation to solve alone. Our topics on clinical trial data and patient adherence are aligned with our principle of putting patients at the centre of our work. And the topics on artificial intelligence contribute our goal of linking up with other sectors active in health research.’

IMI2 – Call 23 is a standard, two-stage Call for proposals with the following topics:

Returning clinical trial data to participants – Clinical trials and studies generate vast amounts of high quality data, yet it is rarely returned to the people taking part in the trial. The aim of this topic is to develop a prototype process to return clinical trial data to study participants, taking into account legal, ethical and data protection issues. Patients would then be able to include the data in their health record where it would help them and their clinicians in decision making. They could also contribute it to additional studies, e.g. through ‘patient-powered research’, which is particularly relevant for rare diseases where treatments and data are scarce.

Modelling the impact of monoclonal antibodies and vaccines on the antimicrobial resistance (AMR) – Monoclonal antibodies (mAb) and vaccines could help to tackle AMR, but assessing different mAbs and vaccines and their potential impacts on AMR is far from easy. The goal of this topic is to develop a mathematical model capable of realistically assessing which vaccines and mAbs have the best chance of reducing AMR and the associated health and economic impacts. The model will take into account the concerns of different stakeholders (e.g. the industry and public health bodies), and will be made publicly accessible. This topic is part of IMI’s AMR Accelerator programme.

A platform to advance neurodegenerative disease biomarker research – Researchers worldwide have amassed a wealth of biological samples and data that could be used to advance research into biological markers for neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases. This topic aims to create a platform that will make it possible for researchers to see what samples and data are available and access them for further research. The hope is that by opening up these samples and data, researchers will be able to discover new biomarkers that will ultimately help to diagnose patients, monitor their disease, and select the most appropriate treatment.

Using artificial intelligence (AI) to select the best cancer treatment – Advances in research mean that for many cancers, there are more treatment options than ever. Physicians face a growing number of potential therapeutic options, each of which needs to be understood and adopted effectively to ensure each patient receives the right treatment. The goal of this topic is to develop a treatment decision support tool with AI technologies to support decision making and research for cancer. The topic focuses on breast, lung and prostate cancer as there are large numbers of patients, a high unmet medical need, and a rapidly evolving treatment environment. However, it should be possible to apply the project outputs to other cancers afterwards.

IMI2 – Call 22 the goal of this single-stage Call is to provide additional support to certain existing IMI2 projects to allow them to build on their achievements and maximise the impacts of their work.

  • IMI2-2020-22-01: Restricted Call to maximise impact of IMI JU objectives and scientific priorities

IMI2 – Call 23 is a standard, two-stage Call for proposals with the following topics:

  • IMI2-2020-23-01: Returning Clinical Trial Data to study participants within a GDPR compliant and approved ethical framework
  • IMI2-2020-23-02: Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance
  • IMI2-2020-23-03: A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases
  • IMI2-2020-23-04: Optimal treatment for patients with solid tumours in Europe through Artificial Intelligence
  • IMI2-2020-23-05: Shortening the path to Rare Disease diagnosis by using newborn genetic screening and digital technologies
  • IMI2-2020-23-06: Behavioural Model of Factors Affecting Patient Adherence
imi2
Deadline: 
29/09/2020
  • ministero dell'istruzione dell'universita e della ricerca
  • regione fvg
  • Area Science Park
  • ProESOF 2020